Anti-IgD Antibodies Modulate Th1 Immune Responses

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune diseases, inflammatory diseases, and allergy-related diseases are limited by significant side effects, long-term graft rejection issues, and inefficiencies in existing immunosuppressive drugs, as well as the risks associated with using pooled human serum immunoglobulins for therapy.

Innovation Solution

The specific binding of surface membrane IgD using anti-IgD antibodies inhibits the expression of Th1 cytokines and transcription factors, such as GM-CSF and T-Bet, thereby modulating immune responses and providing new methods for treatment, diagnosis, and susceptibility assessment of T-helper cell and monocyte lineage-mediated immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing immunosuppressive drugs are used to treat autoimmune diseases, then immune responses are suppressed, but significant side effects occur

Engineering Contradiction:

Improveeffectiveness of immune suppressionVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention targets specific Th1 cytokines (IFN-γ, IL-2, TNF-α) and transcription factors (T-bet, STAT4) with high specificity, rather than using broad-spectrum immunosuppressants. This localized targeting achieves effective immune suppression while minimizing off-target side effects through antibody-mediated neutralization of specific pathogenic molecules.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The invention introduces monoclonal antibodies as intermediary molecules that specifically bind to and neutralize Th1 cytokines and transcription factors. These antibodies act as mediators between the immune system components, blocking harmful Th1-mediated responses without requiring direct contact between immune cells, thereby reducing side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If pooled human serum immunoglobulins are used for therapy, then immune responses are modulated, but risks of transmission of diseases occur

Engineering Contradiction:

Improvetherapeutic effectVSAvoiddisease transmission risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention uses recombinant monoclonal antibodies that can be produced in controlled cell culture systems, replacing pooled human serum immunoglobulins. These monoclonal antibodies are essentially 'disposable' therapeutic agents that can be manufactured fresh, ensuring no transmission of human diseases while maintaining therapeutic efficacy.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The invention replaces the biological 'mechanical system' of pooled human serum (which physically contains potential pathogens) with a biologically engineered system of recombinant monoclonal antibodies produced in controlled environments, eliminating the transmission risk while preserving the immunomodulatory function.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If Th1 immunity is activated to fight infections, then pathogen clearance is improved, but autoimmune diseases and inflammatory conditions are exacerbated

Engineering Contradiction:

Improvepathogen clearance capabilityVSAvoidautoimmune pathology

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The invention applies partial action by selectively neutralizing only the excessive or pathogenic Th1 responses (through anti-IFN-γ, anti-IL-2, anti-TNF-α antibodies) rather than suppressing all Th1 immunity. This allows beneficial Th1-mediated pathogen clearance to continue while blocking the harmful autoimmune manifestations.

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The invention changes the parameter balance of the immune response by specifically reducing Th1 cytokine levels (IFN-γ, IL-2, TNF-α) and transcription factor activity (T-bet, STAT4) through targeted antibody binding. This parameter modulation shifts the immune balance away from pathogenic Th1 dominance while preserving essential immune functions.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively suppresses Th1 immune responses, reducing the risk of autoimmune disease pathogenesis and inflammation, while offering a safer and more effective alternative to existing treatments by specifically targeting Th1 cytokines and transcription factors.

Implementation Method 1

The specific binding of surface membrane IgD using anti-IgD antibodies inhibits the expression of Th1 cytokines and transcription factors

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS9156916B2Modulation of T helper cell-mediated immune responses

Publication Date: 2015.10.13 AIGD BIOTECH PTY LTD

AI summary

Provided herein are methods for modulating one or more of a T-helper cell or monocyte lineage cell-mediated immune response in a subject, the method comprises administering to the subject an effective amount of a compound which binds to surface membrane immunoglobulin D (smIgD). Also provided are methods of diagnosis of one or more of a T-helper cell or monocyte lineage cell-mediated immune disease, and compositions and kits for use in such methods.